Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ompenaclid in RAS Mutant Advanced or Metastatic Colorectal Cancer
NCT05983367Phase 2Terminated
- Sponsor
- Inspirna
- Start
- Oct 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of ompenaclid in colorectal cancer (CRC), sponsored by Inspirna. Started Oct 2023; status: terminated.
02
Drugs
ompenaclid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05983367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05983367.